Skip to main content
. 2019 Apr 12;14(5):882–892. doi: 10.1021/acschembio.8b01016

Figure 4.

Figure 4

HaloPROTAC-mediated degradation of HaloTag7-fusion proteins. A. SGK3-Halo and Halo-VPS34 cell lines were treated for 48h with increasing concentrations of each HaloPROTAC in parallel. Degradation of target protein measured by Immunoblot analysis for HaloTag7. B and C. Quantification of Western Blot intensity from A for SGK3-Halo (B) or Halo-VPS34 (C). Protein intensity was quantified and presented relative to an untreated control. D. SGK3-Halo and Halo-VPS34 cells were treated for up to 24 h with 300 nM HaloPROTAC-E. One hour before lysis, all conditions were treated with 1 μM AZD5363 to inhibit Akt activity. Cells were lysed and lysates analyzed by Immunoblot with the antibodies specified.